9月16日，Twist Bioscience盘前上涨5.72%，报146.0美元/股，成交额11.2万美元。
消息面上，在贝尔德主办的全球医疗健康大会上，公司CEO透露第四财季营收预计约1.24亿美元，同比增长约25%，即连续15个季度实现营收增长；同时披露当前AI制药相关订单已达5000万美元，预计明年将翻番至1亿美元。公司长期计划到2031年实现收入翻番，隐含年复合增长率约15%，并推进2.5亿美元增发计划以扩充DNA合成产能。此前公司已被Anthropic选定为AI蛋白质设计项目的独立实验服务商，自8月以来股价累计涨超50%。瑞银近期首次覆盖给予中性评级，目标价144美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.